Sunnyvale, Calif. (BUSINESS WIRE)February 22, 2006 The benefits of Intraop Medical Corporation's (OTCBB: IOPM) Mobetron® mobile electron-beam system continues to receive clinical validation. A recent study involved 651 men and women with locally advanced rectal cancer who received Intraoperative Radiation Therapy (IORT) as part of their treatment. The results indicated excellent overall survival rates and tumor control for this hard-to-treat patient group.

"Colorectal cancer is the third largest cancer in both men and women in the U.S., with more than 56,000 patients dying of this disease each year," said Dr. Donald A. Goer, President and CEO of Intraop. "When detected early, colorectal cancer is highly curable, with survival rates approaching 90%. However, if the cancer is detected when the disease is more advanced, such as was the case for the patients in this study, the prognosis is much worse. With the standard treatment of chemoradiation therapy and surgery for advanced rectal cancer, only 25% of patients are expected to survive five years, and tumors recur in more than 50% of these patients, requiring additional surgery, hospitalization and treatment."

The results of this study showed substantial benefit when IORT complements standard treatments. Patients treated with IORT in addition to the standard treatment experienced substantial improvements in survival rates and had fewer tumor recurrences. Five year overall survival rates jumped to 67% and ten year survival rates rose to 46%, while five and ten year tumor-control rates climbed to 88% and 86% respectively.

The study's principal investigator, Dr. Harm Rutten, Chief of Surgery at Catharina Zeikenhuis in Eindhoven, Holland, commented: "These results are truly exceptional. As a surgeon who treats many patients with this advanced disease, it is gratifying to have a tool that can help these patients and save their lives."

This extensive study of locally advanced rectal cancer patients conducted by four major European referral centers, all members of the International Society of IORT-Europe (ISIORT-Europe) is the largest ever reported in the medical literature, and the largest ever involving IORT. It represents the second pooled analysis by the ISIORT-Europe on the clinical outcome of IORT treatments.

"Since tumor control with IORT is so dramatically improved, this is a most important study that represents a triple-win: a win for the patient, a win for their doctor and a major win for cost-effective healthcare," said Dr. Goer. "We believe this study strengthens the evidence that IORT and the Mobetron present us with a major advance in cancer treatment."

Dr. Harm Rutten, Chairman of Surgery at Catharina Ziekenhuis in Eindhoven, presented the results of this study in Berlin at the European Colorectal Cancer Congress. In the months ahead the ISIORT-Europe is planning to present the results of IORT on other tumor sites. As analyses become available, they will be posted on the ISIORT web site: www.isiort.org

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.